English

BioStock: Brain+ CEO - “CST is becoming the standard in dementia care”

Report this content

Brain+ is a health tech company focused on treatment and management of dementia. Centred around Cognitive Stimulation Therapy, the company’s approach has the potential to revolutionize dementia care. CEO Kim Baden-Kristensen stopped by the BioStock Studio to talk about Brain+’s path-to-market and the future of dementia management.

Watch the interview with Brain+‘s CEO Kim Baden-Kristensen at biostock.se:

Brain+ CEO: "CST is becoming the standard in dementia care" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Brain+ CEO - “CST is becoming the standard in dementia care”
Tweet this